Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.
On day 2 of the Association of Community Cancer Centers’ 49th Annual Meeting and Cancer Center Business Summit, Andre Harvin, PharmD, MS, MBA, executive director of pharmacy, Oncology Services, Cone Health Cancer Center, will deliver the keynote address, “Robots, Biologics, and Advocates: Lessons from the Pharmacy.”
In this interview with The American Journal of Managed Care®, he discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.
Transcript
What can pharmacy’s use of robots, biologics, and advocates teach us about streamlining and improving the patient experience?
My keynote address is really about bringing pharmacy to the light. I think most people understand that we’re a really strong support service. What I’m going to do is really say that we play such a critical role that sometimes goes unappreciated. One of my mentors told me a long time ago, he said, “Pharmacy is kind of like the spine of the hospital system: You don’t really think about your spine, but so much is dependent on it, right? Your nerves flow through your spine, your muscles attach to it, but for the most part, if everything’s going well, you never think about your spine. You only think about it when something goes wrong, and then by that point in time, something may be amiss.”
My goal is to really say, “Let’s start to take care of our backs. Let’s make sure we get some stretches in the morning, some downward dogs, some cat-cows, those kind of things, really every day to have that appreciation of what pharmacy brings to the table.” What I’m going to do is I’m going to highlight 3 areas, and only 3 select areas, that we’ve utilized to impact our oncology cancer center and the patients that we serve.
When we think about biologics, we’re going to talk about biosimilars. We’re going to talk about not only the finances around that but the patient access that we’ve been able to create and amplify because of that.
With our robots, not everyone’s going to have a robot, but it’s about how we leverage data and how we leverage our operations to help move our patients through their visits faster, allowing us to treat more patients and allowing us to respect patients, so that when we say, “Hey, you have an appointment that’s an hour long,” they can expect to be there for an hour and not 2 hours at that point in time.
And then finally, that advocacy piece is that pharmacists can be a strong advocate for the patients, whether that’s helping them ensure they can pay for their medication or provide critical education that is unique to a pharmacist.
All of these 3 together are 3 small things pharmacists do on a day-in/day-out basis that I have the privilege to really talk to everyone about today and make sure that they understand the impact that pharmacy has as well.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More